Spravato

Roseville Center for Interventional Psychiatry

What is Spravato?

A New Approach to Treatment-Resistant Depression

Millions of Americans deal with depression, and many of them have major depressive disorder (MDD). For about one-third of those with MDD, traditional antidepressants just don’t work. This is called treatment-resistant depression (TRD), and finding the right treatment can be very hard.

Spravato, an FDA-approved nasal spray, offers a new way to treat TRD. Unlike regular antidepressants, which can take weeks to start working, Spravato can help improve mood in just hours or days. It’s administered in a clinic and typically works best in conjunction with other antidepressants.

Spravato (esketamine) medication works by affecting glutamate, a neurotransmitter responsible for helping control mood. For people with treatment-resistant depression, Spravato nasal spray is a new option. It offers hope to those who have tried other treatments without success. With its fast results and potential for lasting improvement, Spravato therapy can make a big difference in the lives of those who need it most.

A Clinically Proven Solution

Spravato (esketamine), also known as esketamine, shares similarities with ketamine, an FDA-approved anesthetic with over 60 years of history. Ketamine has been used for years to treat depression, TRD, anxiety, and PTSD, with leading physicians nationwide achieving remarkable success with ketamine treatments. With the recent FDA approval of Spravato, most insurance plans cover treatment costs for eligible patients, with only co-pay and co-share as specified by insurance policies.

Spravato (esketamine) treatment for depression is thought to work by facilitating the growth of new neural pathways, placing the brain in a state of neuroplasticity. Neuroplasticity allows for our minds to create thinking patterns and engage in new positive routines that alleviate depression. Traditional oral antidepressants typically work on serotonin, norepinephrine neurotransmitters in the brain, however, Spravato (esketamine) acts on an entirely different neurotransmitter called glutamate. Glutamate regulates emotions, memory, neuroplasticity, and other cognitive processes. It also stimulates the growth of new synapses (neural connections) between brain cells.

Research studies show that FDA-approved Spravato treatment for depression is highly effective and rapid-acting.

Spravato (esketamine) is an innovative and newer approach that very often works even in individuals that have not benefited from multiple trials of different oral antidepressants. It is specifically FDA-approved to treat Treatment-Resistant Depression (TRD) and Major Depressive Disorder (MDD)

How does it work?

Treatment Process

Step 1

Initial Consultation

Begin with an initial consultation to discuss your medical history, mental health concerns, and treatment goals with our clinician.

Step 2

Treatment Plan

Based on the assessment, receive a prescription for Spravato and a personalized treatment plan tailored to your needs.

Step 3

Spravato Administration Sessions

Self-administer Spravato under supervision at our clinic, following instructions provided by our healthcare team.

Step 4

Ongoing Monitoring

Experience ongoing monitoring of your response to Spravato and attend follow-up appointments to assess progress and make any necessary adjustments to your treatment plan.

Compare Spravato versus IV Ketamine

Spravato (esketamine) therapy and IV ketamine are both options for treating depression and used specifically for treatment-resistant depression when other treatments haven’t helped. While they have similarities, they differ in how they’re given, how well they work, insurance coverage, and the overall experience. Understanding these differences can help you figure out which one is right for you.

Spravato is an FDA-approved nasal spray and used along with an antidepressant to treat adults with treatment-resistant depression (TRD) and major depression with suicidal thoughts. Unlike traditional antidepressants that can take weeks to kick in, Spravato may start working within hours or days. Approved in 2019, it has helped many people who haven’t had success with other medications. Because of its FDA approval, most insurance plans cover Spravato, making it a more affordable option for many.

IV ketamine has been used in hospitals for years as an anesthetic, and more recently, doctors have been using it off-label to help with depression, anxiety, and PTSD. This treatment is given through an IV drip over 40 to 60 minutes in a clinic. Unlike Spravato, IV ketamine is not FDA-approved for depression, so insurance usually doesn’t cover it. However, many doctors have seen positive results in patients using IV ketamine for mental health conditions.

The biggest differences between Spravato and IV ketamine are how they’re taken and insurance coverage. Spravato is a self-administered nasal spray used under supervision at a certified clinic, while IV ketamine is administered through an IV. Spravato is usually taken twice a week for four weeks, then once a week or every other week, depending on how well it’s working. IV ketamine is typically given in six sessions over two to three weeks, followed by maintenance treatments as needed. Both treatments work fast, but IV ketamine may take effect even quicker, while Spravato follows a structured, long-term approach with FDA approval.

Choosing between Spravato and IV ketamine depends on what you need.

If you want an FDA-approved treatment that’s covered by insurance, Spravato may be your best bet. If you’re looking for a possibly faster-acting option and are okay with paying out-of-pocket, IV ketamine could be worth considering.

If you have been searching for Spravato treatment near Roseville, Roseville Center for Interventional Psychiatry is here to help. We specialize in Spravato therapy and provide a safe, supportive space for your mental health journey. If you’re struggling with TRD, you don’t have to go through it alone. Both Spravato and IV ketamine offer hope when other treatments haven’t worked. Reach out to us and let’s find the best path forward together.

Compare TMS versus Spravato and IV Ketamine

TMS, Spravato, and IV ketamine are all options for treating depression, especially for individuals suffering from treatment-resistant depression who haven’t been able to find relief using regular antidepressants. As with any treatment, each offers its own pros and cons. Transcranial Magnetic Stimulation (TMS) is a non-invasive treatment that uses magnetic pulses to stimulate areas of the brain that control mood. Unlike medications or electroconvulsive therapy (ECT), TMS doesn’t require anesthesia and has very few side effects. TMS sessions last about 20 to 40 minutes and happen five days a week for several weeks. Many people see improvement without the side effects that often come with medication.

Spravato (esketamine) is an FDA-approved nasal spray used in conjunction with an oral antidepressant for adults suffering from treatment-resistant depression (TRD). It works differently from traditional antidepressants by affecting glutamate, a key chemical in the brain. Spravato is given at certified treatment centers, where patients are monitored for about two hours after each dose. Most insurance plans cover Spravato, making it a good option for many.

IV ketamine has been used as an anesthetic for years and more recently as an off-label treatment for depression, anxiety, and PTSD. It’s given through an IV over 40 to 60 minutes and may provide fast relief for some people. However, IV ketamine is not FDA-approved for depression, so insurance usually doesn’t cover it. Still, many doctors have seen positive results using it for mental health.

The biggest differences between these treatments are how they’re given and insurance coverage. TMS is non-invasive and doesn’t use medication. Spravato is a nasal spray taken under supervision. IV ketamine is given through an IV. TMS and Spravato are FDA-approved, so insurance is more likely to cover them, while IV ketamine is often an out-of-pocket expense.

Choosing between TMS, Spravato, and IV ketamine depends on what works best for you. If you want a non-medication option with few side effects, TMS may be the right choice. If you prefer an FDA-approved medication covered by insurance, Spravato could be a good fit. And if you are looking for something that might work quickly and are able to pay for treatment out-of-pocket, IV ketamine might be worth trying.

Whatever route you choose, Roseville Center for Interventional Psychiatry is here to help navigate the best treatment for you. Contact us today to learn more and take the next step toward feeling better.

FAQ's

Frequently Asked Questions

These FAQs provide basic information about Roseville Center and treatments offered, but patients should always consult their healthcare provider for personalized advice and guidance.

WHAT IS SPRAVATO ?

Spravato is a prescription nasal spray used alongside an antidepressant to treat treatment-resistant depression (TRD) and depressive symptoms in adults with major depressive disorder (MDD) and suicidal thoughts or actions.

IS SPRAVATO RIGHT FOR ME?

Spravato is FDA-approved for adults with depression who haven’t responded well to other treatments, specifically those with treatment-resistant depression. Contact Roseville Center for Interventional Psychiatry to discuss your situation and treatment options.

WHERE DO I GET SPRAVATO?

Spravato is administered under medical supervision at certified clinics or doctor’s offices. Roseville Center for Interventional Psychiatry is a certified provider.

DO I QUALIFY FOR TREATMENT WITH SPRAVATO?

Spravato is approved for adults with treatment-resistant depression. Your doctor will determine your eligibility. Contact Roseville Center for more information.

DOES MY INSURANCE COVER SPRAVATO?

Most insurance plans cover Spravato. Our Patient Advocates will help minimize out-of-pocket costs and manage insurance paperwork.

HOW CAN I GET MORE INFORMATION ABOUT SPRAVATO?

Contact Roseville Center or visit www.spravato.com for more information from Janssen Pharmaceuticals, Inc.